ValuEngine downgraded shares of Intellia Therapeutics (NASDAQ:NTLA) from a hold rating to a sell rating in a research note released on Wednesday, November 15th.
NTLA has been the topic of several other research reports. Credit Suisse Group lifted their price objective on Intellia Therapeutics from $24.00 to $28.00 and gave the stock an outperform rating in a report on Friday, November 3rd. Jefferies Group set a $42.00 price target on Intellia Therapeutics and gave the company a buy rating in a report on Tuesday, October 31st. Leerink Swann boosted their price target on Intellia Therapeutics from $29.00 to $37.00 and gave the company an outperform rating in a report on Tuesday, October 31st. They noted that the move was a valuation call. Wedbush restated an ourperform rating and set a $25.00 price target (down previously from $29.00) on shares of Intellia Therapeutics in a report on Wednesday, September 27th. Finally, Zacks Investment Research upgraded Intellia Therapeutics from a sell rating to a hold rating in a report on Wednesday, October 4th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the company. The stock has an average rating of Hold and an average price target of $30.17.
Intellia Therapeutics (NTLA) opened at $23.00 on Wednesday. Intellia Therapeutics has a twelve month low of $10.83 and a twelve month high of $33.34.
Several hedge funds have recently bought and sold shares of the business. GSA Capital Partners LLP grew its holdings in shares of Intellia Therapeutics by 28.9% during the 3rd quarter. GSA Capital Partners LLP now owns 73,100 shares of the company’s stock worth $1,817,000 after acquiring an additional 16,400 shares during the period. Neuberger Berman Group LLC grew its holdings in shares of Intellia Therapeutics by 23.0% during the 3rd quarter. Neuberger Berman Group LLC now owns 60,915 shares of the company’s stock worth $1,514,000 after acquiring an additional 11,398 shares during the period. Granahan Investment Management Inc. MA grew its holdings in shares of Intellia Therapeutics by 7.0% during the 3rd quarter. Granahan Investment Management Inc. MA now owns 286,144 shares of the company’s stock worth $7,111,000 after acquiring an additional 18,784 shares during the period. Schwab Charles Investment Management Inc. grew its holdings in shares of Intellia Therapeutics by 34.7% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 57,492 shares of the company’s stock worth $1,429,000 after acquiring an additional 14,818 shares during the period. Finally, GMT Capital Corp bought a new stake in shares of Intellia Therapeutics in the 3rd quarter worth approximately $8,214,000. Hedge funds and other institutional investors own 49.49% of the company’s stock.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Intellia Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.